Reliance Industries lifts Indian shares higher

10 Jul 2023
www.reuters.com
Financial Statement
BENGALURU, July 10 (Reuters) - Indian shares advanced on Monday, as a broad sectoral decline was offset by heaavyweight Reliance Industries as it firmed plans on the demerger of its financial services business and its retail unit approved a reduction in equity share capital. The Nifty 50 (.NSEI) index settled 0.12% higher at 19,355.90, while the S&P BSE Sensex (.BSESN) rose 0.10% to 65,344.17. Only two of the 13 major sectoral indexes logged gains with metals (.NIFTYMET) rising over 1.5% and oil and gas (.NIFOILGAS) rising over 0.5%. The rise was led by the oil-to-retail conglomerate Reliance Industries (RELI.NS), which climbed nearly 4% after the company's unit Reliance Retail approved a share capital reduction. The retail arm is reported to have been valued at $92-$96 billion by two global consultants, in a move that could hint at an eventual public offer. The company also set July 20 as the record date for the demerger of its financial services business into Reliance Strategic Investments. This demerger has "value-unlocking potential" for the company, per analysts. Information technology (IT) index lost over 1%. "IT firms are likely to post weak June quarter earnings while margin pressures will continue," said Saptarishi Mukherjee, assistant vice president for research at BOB Capital Markets. The brokerage cut ratings on HCLTech (HCLT.NS), Persistent Systems (PERS.NS), Coforge (COFO.NS) and Affle India (AFFL.NS) to "hold" from "buy" and flagged more earnings downgrades in the sector post the June quarter results due to a reduction in clients' spending. Tata Consultancy Services (TCS.NS) and HCLTech will report their June quarter numbers on July 12 while Wipro's earnings are due on July 13. HCLTech and Tata Consultancy Services were among the top Nifty 50 losers. Titan Company (TITN.NS) lost over 3% and was also among the top Nifty 50 losers after global brokerage Morgan Stanley flagged concerns about jewellery demand. ($1 = 82.6100 Indian rupees) Reporting by Bharath Rajeswaran in Bengaluru; Editing by Dhanya Ann Thoppil and Nivedita Bhattacharjee Our Standards: The Thomson Reuters Trust Principles.
For more details,please visit the original website
The content of the article does not represent any opinions of Synapse and its affiliated companies. If there is any copyright infringement or error, please contact us, and we will deal with it within 24 hours.
Organizations
Indications
-
Targets
-
Drugs
-
Chat with Hiro
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.